Clinical trials
Observational Adenocarcinoma trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 4 |
| Terminated | 4 |
| Withdrawn | 3 |
| Active, not recruiting | 1 |
| Unknown status | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stanford University | 6 |
| Mayo Clinic | 3 |
| Memorial Sloan Kettering Cancer Center | 2 |
| AstraZeneca | 1 |
| Boston Scientific Corporation | 1 |
| Castle Biosciences Incorporated | 1 |
| Cook Research Incorporated | 1 |
| Edward Hospital | 1 |
| Edward-Elmhurst Health System | 1 |
| Gary Onik MD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adenocarcinoma | 30 |
| Carcinoma | 9 |
| Prostatic Neoplasms | 9 |
| Carcinoma, Squamous Cell | 7 |
| Sarcoma | 7 |
| Melanoma | 5 |
| Neoplasms | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Esophageal Neoplasms | 4 |
| Lung Neoplasms | 4 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.